NASDAQ:ESTA - Establishment Labs Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$22.10 -2.34 (-9.57 %)
(As of 05/23/2019 03:43 PM ET)
Previous Close$24.44
Today's Range$21.67 - $25.61
52-Week Range$20.05 - $30.70
Volume218,823 shs
Average Volume59,296 shs
Market Capitalization$451.06 million
P/E RatioN/A
Dividend YieldN/A
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue. The company sells its products through exclusive distributors and direct sales force in 60 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.

Receive ESTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ESTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolNASDAQ:ESTA



Sales & Book Value

Annual Sales$61.21 million
Book Value$2.99 per share


Net Income$-21,100,000.00


Market Cap$451.06 million
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable

Establishment Labs (NASDAQ:ESTA) Frequently Asked Questions

What is Establishment Labs' stock symbol?

Establishment Labs trades on the NASDAQ under the ticker symbol "ESTA."

How were Establishment Labs' earnings last quarter?

Establishment Labs Holdings Inc (NASDAQ:ESTA) posted its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.13. The firm earned $20.78 million during the quarter, compared to analyst estimates of $18.50 million. Establishment Labs had a negative return on equity of 68.22% and a negative net margin of 37.74%. View Establishment Labs' Earnings History.

When is Establishment Labs' next earnings date?

Establishment Labs is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Establishment Labs.

What guidance has Establishment Labs issued on next quarter's earnings?

Establishment Labs issued an update on its FY 2019 earnings guidance on Wednesday, May, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80-84 million, compared to the consensus revenue estimate of $77 million.

What price target have analysts set for ESTA?

3 equities research analysts have issued 1-year target prices for Establishment Labs' shares. Their predictions range from $35.00 to $40.00. On average, they anticipate Establishment Labs' share price to reach $36.6667 in the next twelve months. This suggests a possible upside of 65.9% from the stock's current price. View Analyst Price Targets for Establishment Labs.

What is the consensus analysts' recommendation for Establishment Labs?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Establishment Labs in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Establishment Labs.

What are Wall Street analysts saying about Establishment Labs stock?

Here are some recent quotes from research analysts about Establishment Labs stock:
  • 1. BTIG Research analysts commented, "Establishment reported impressive Q1 sales of ~$21M, besting consensus of $18M. Heading into the quarter, we felt there was a very strong likelihood of a beat but the magnitude of the sequential bump (27%) was surprising. We are encouraged that quarterly improvement was spurred by strong underlying demand in W. Europe, Brazil, and S. Korea – less so, it seems from any pull forward benefit in Q1. Even with a strong start, guidance was set at $80-84M for FY19, implying little improvement over Q1 results. We understand the conservatism around quarterly lumpiness and seasonality, but we still see a few areas that can drive upside, particularly in the second half: 1) the ramp in 2) ongoing transition to direct sales, and 3) share gains in W. Europe following the fall-out of textured implants. We model FY19 revenue above guidance at $86M." (5/16/2019)
  • 2. According to Zacks Investment Research, "Establishment Labs Holdings Inc. is a medical technology company. It focuses on designing, developing, manufacturing and marketing portfolio of silicone gel-filled breast implants ae well as body shaping implants. The company's brand consists of Motiva Implants(R) and MotivaImagine (R) platform. Its technologies portfolio includes Divina 3D Simulation System(R), Puregraft and MotivaImagine Centers (R). Establishment Labs Holdings Inc. is based in NEW YORK. " (10/15/2018)

Has Establishment Labs been receiving favorable news coverage?

News stories about ESTA stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Establishment Labs earned a news impact score of 0.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the next few days.

Are investors shorting Establishment Labs?

Establishment Labs saw a increase in short interest in April. As of April 15th, there was short interest totalling 688,825 shares, an increase of 32.0% from the March 29th total of 521,925 shares. Based on an average daily trading volume, of 122,401 shares, the days-to-cover ratio is presently 5.6 days. Currently, 7.3% of the company's shares are sold short. View Establishment Labs' Current Options Chain.

Who are some of Establishment Labs' key competitors?

What other stocks do shareholders of Establishment Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Establishment Labs investors own include athenahealth (ATHN), Evolus (EOLS), Sientra (SIEN), Allergan (AGN), Conduent (CNDT), Chevron (CVX), Johnson & Johnson (JNJ), Thermo Fisher Scientific (TMO), Basf (BAS) and iShares Core MSCI EAFE ETF (IEFA).

Who are Establishment Labs' key executives?

Establishment Labs' management team includes the folowing people:
  • Mr. Juan Jose Chacon Quiros, Founder, CEO & Exec. Director (Age 47)
  • Mr. Salvador Santos Dada, Chief Operating Officer (Age 37)
  • Mr. Eddie De Oliveira, VP of Sales, Brazil (Age 36)
  • Ms. Renee M. Gaeta, Chief Financial Officer (Age 38)
  • Mr. Roberto De Mezerville, Chief Technology Officer (Age 39)

When did Establishment Labs IPO?

(ESTA) raised $50 million in an initial public offering on Thursday, July 19th 2018. The company issued 3,100,000 shares at $15.00-$17.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and BTIG was co-manager.

Who are Establishment Labs' major shareholders?

Establishment Labs' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.98%), Opaleye Management Inc. (0.25%), MYDA Advisors LLC (0.15%), Northern Trust Corp (0.12%), JPMorgan Chase & Co. (0.03%) and BlackRock Inc. (0.03%).

Which major investors are selling Establishment Labs stock?

ESTA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC and MYDA Advisors LLC.

Which major investors are buying Establishment Labs stock?

ESTA stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Northern Trust Corp, JPMorgan Chase & Co. and Morgan Stanley.

How do I buy shares of Establishment Labs?

Shares of ESTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Establishment Labs' stock price today?

One share of ESTA stock can currently be purchased for approximately $22.0999.

How big of a company is Establishment Labs?

Establishment Labs has a market capitalization of $451.06 million and generates $61.21 million in revenue each year. The company earns $-21,100,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Establishment Labs employs 505 workers across the globe.

What is Establishment Labs' official website?

The official website for Establishment Labs is

How can I contact Establishment Labs?

Establishment Labs' mailing address is PO BOX 3140 COMMERCE HOUSE, ROAD TOWN D8, VG1110. The company can be reached via phone at 50624342400 or via email at [email protected]

MarketBeat Community Rating for Establishment Labs (NASDAQ ESTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about Establishment Labs and other stocks. Vote "Outperform" if you believe ESTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/23/2019 by Staff

Featured Article: Put Option Volume

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel